Loading...
Market
Story
Sanofi to Revise U.S. 340B Drug Discount Program for Low-Income Hospitals Next Year
Nov 22, 2024, 09:05 PM
Sanofi, a French pharmaceutical company, is set to modify its approach to the U.S. 340B drug discount program, which provides discounts to hospitals serving low-income and uninsured patients. Starting next year, the company plans to require hospitals to submit detailed pharmacy and medical claims, including patient information, for review before receiving discounts. This move intensifies an industry fight against lucrative drug discounts for hospitals. Sanofi's decision follows similar actions by Johnson & Johnson and Eli Lilly, indicating a trend among major pharmaceutical companies to alter how they provide discounts under the 340B program.
View original story
Similar markets
Price caps • 25%
Transparency requirements • 25%
Market share limits • 25%
No action • 25%
Public condemnation • 25%
Private negotiations • 25%
No response • 25%
Increased funding • 25%
Increased oversight • 25%
Reduced oversight • 25%
No significant changes • 25%
Other changes • 25%
OptumRx • 25%
Express Scripts • 25%
CVS Caremark • 25%
Other • 25%
Impose fines • 25%
Ban future collaborations • 25%
Issue warnings • 25%
No action taken • 25%
Yes • 50%
No • 50%
Announce internal policy changes • 25%
Face additional lawsuits • 25%
No significant actions taken • 25%
Announce new partnerships or acquisitions • 25%
Fines imposed • 25%
Regulations introduced • 25%
No action taken • 25%
Other • 25%
Yes • 50%
No • 50%
CVS Caremark • 25%
Express Scripts • 25%
OptumRx • 25%
Other • 25%